Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention IDH-mutant astrocytoma and oligodendroglioma, the most common co-covered peer. vorasidenib appears in 1 tracked Biotech story from August 2, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about vorasidenib
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention IDH-mutant astrocytoma and oligodendroglioma, the most common co-covered peer. vorasidenib appears in 1 tracked Biotech story from August 2, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering vorasidenib. Shared-story counts are live from our verified record — not editorial picks.
The PBS listing of Servier’s vorasidenib transforms a $28,000/month orphan drug into a mass-market treatment, commercializing the first IDH inhibitor for brain cancer in two decades. This regulatory win validates the IDH pathway and could ignite further investment in rare neuro-oncology pipelines, as Australia’s move signals payer willingness to cover high-cost precision therapies.
